Peptides for Brain Function: What Crosses, What Works, What Does Not

Almost every peptide sold for cognition fails at the first hurdle, and it is not an evidence hurdle. It is a physical one. The blood brain barrier exists to keep large water loving molecules out of neural tissue, and peptides are large water loving molecules. Before asking whether a compound improves memory or focus, ask whether it reaches the brain at all.

That filter removes most of the category. What survives is a short list: two Russian nasal sprays, one rodent compound with extraordinary claims and no human data, and a clinical preparation most people have never heard of. This page covers the survivors, ranked by evidence, with the shortfalls stated rather than buried.

The Blood Brain Barrier Is the Whole Problem

The barrier is a layer of endothelial cells joined by tight junctions, and it admits small lipid soluble molecules readily while excluding almost everything else without a dedicated transporter. Peptides have neither the size nor the lipophilicity to get through passively, and most have no transporter waiting for them.

There are three ways around it, and only one is practical outside a hospital.

• Be very small and very stable. Semax and selank are both seven amino acids long, engineered from natural fragments with modifications that slow enzymatic breakdown. Short and stable is the minimum entry requirement.
• Use the nose. Intranasal delivery exploits the olfactory and trigeminal pathways, a partial route into the central nervous system that sidesteps systemic circulation. This is why the credible compounds here are sprays rather than injections, and it is not a marketing preference.
• Be lipidised or carrier bound. Dihexa's hexanoic acid tail exists for this reason. A real chemical strategy, but not one that makes a compound safe or effective on its own.

Apply that filter honestly and a lot of popular recommendations collapse. BPC-157 has essentially no case for direct central action at normal doses, and growth hormone secretagogues reach the brain only indirectly through sleep quality. If a vendor page claims cognitive benefits for a compound with no delivery story, that is the tell.

Semax: The Most Studied of a Thin Field

Semax is a synthetic analogue of the ACTH(4-10) fragment, stripped of hormonal activity and stabilised with a proline glycine proline tail that resists peptidase cleavage. Developed at the Institute of Molecular Genetics in Moscow, it is registered in Russia and Ukraine for stroke, optic nerve conditions and cognitive disorders, and approved nowhere in Western Europe or North America.

The mechanism that matters is neurotrophic. Semax raises hippocampal expression of brain derived neurotrophic factor and its receptor TrkB, and modulates dopaminergic and serotonergic signalling. BDNF is the closest thing this field has to a legitimate lever, since it governs synaptic plasticity and is how exercise produces most of its cognitive benefit.

The caveat is the literature itself. Most of it comes from a small number of Russian groups publishing in Russian language journals, and independent Western replication is sparse. That does not make the findings wrong, but the evidence base is narrower than the citation count suggests.

The common research format is a 0.1 percent intranasal solution, with reported protocols of 200 to 600 micrograms daily split across two or three administrations in two to four week cycles. The N-acetyl amidated variant is more stable and more potent per microgram, which matters before assuming the two are interchangeable. Pantheon lists semax as a lyophilised vial, and our semax guide covers the variants.

Selank: An Anxiolytic That Reads as a Nootropic

Selank is a heptapeptide analogue of tuftsin, an immune signalling fragment, from the same Moscow programme and registered in Russia as an anxiolytic rather than a cognitive drug. That registration is the most useful fact about it.

Its primary action is on GABAergic and serotonergic tone, with some evidence of BDNF involvement. Users frequently describe improved concentration, and the honest reading is that this is downstream of reduced anxiety. When worry consumes working memory, removing it looks exactly like a cognitive improvement. When anxiety is not the limiting factor, selank underwhelms.

It is the gentler of the two, without the stimulating quality semax can have, and they are often run together so selank smooths the edge off semax. Reported protocols mirror semax, typically a 0.15 percent nasal solution at 250 to 750 micrograms daily. Selank is stocked alongside it, and the anxiety picture is covered in our peptides for anxiety breakdown.

Dihexa: Remarkable Rodent Data, Zero Human Trials

Dihexa is where this category gets interesting and where it gets irresponsible. It is an angiotensin IV analogue developed at Washington State University to potentiate hepatocyte growth factor signalling through the c-Met receptor. The reported rodent result is synaptogenesis, the formation of new dendritic spines, at potencies described as orders of magnitude beyond BDNF itself, with cognitively impaired animals recovering maze performance.

Every one of those findings is preclinical. There are no published human trials, no established dose, no pharmacokinetic profile in people, and no long term safety data for a molecule whose entire purpose is driving growth factor signalling. The obvious concern with a potent growth factor potentiator is what else it promotes over years of use, and that question has not been asked in humans, let alone answered.

Community protocols circulate in the 5 to 20 milligram range, oral or transdermal, extrapolated from animal work rather than derived from anything human. Anyone experimenting here is the trial. Dihexa is carried as a research chemical, and our dihexa page covers the preclinical work in depth.

Cerebrolysin: The Clinical End of the Category

Cerebrolysin is not a single peptide but a preparation of low molecular weight peptides and amino acids derived from purified porcine brain protein. Prescribed in parts of Europe and Asia for stroke, brain injury and vascular dementia, it has been studied far more rigorously than anything else here.

The results are genuinely mixed. Some stroke and brain injury trials report benefit on functional outcome scales, while systematic reviews have been cautious to negative, noting heterogeneous methodology and positive results clustering in manufacturer sponsored trials.

It is included as calibration rather than as a recommendation. Cerebrolysin is the one compound here that received real clinical scrutiny, and what that scrutiny produced was ambiguity. Worth holding in mind when judging a category that has never been tested that way at all. It is also a prescription product given intravenously in clinical settings, not something to source informally.

The Bioregulators: Pinealon and Company

The Khavinson bioregulators are very short peptides, often two to four amino acids, proposed to act by binding directly to DNA and modulating gene expression in specific tissues. Pinealon (Glu-Asp-Arg) is the one aimed at neural tissue, with claims around neuroprotection and cognitive maintenance in ageing.

The proposed mechanism is unusual enough to warrant scepticism, and the evidence sits almost entirely with the original Saint Petersburg programme. Against that, the tripeptides are small enough that the delivery objection sinking most of this category does not apply, and the safety profile across decades of Russian use is unremarkable. Courses typically run 10 to 20 days at low oral doses. Pinealon is sold as a research vial, and the wider bioregulator picture is in our longevity peptides guide.

How the Options Compare

Running a Protocol That Actually Tells You Something

The failure mode here is not choosing the wrong compound, it is running an experiment that cannot produce an answer. Cognition is the most suggestible endpoint in the peptide world, because the instrument measuring the effect is the thing being affected. A few rules make the difference between data and guesswork.

• One compound at a time. Stacking semax, selank and a bioregulator on day one guarantees you never learn which one did anything.
• Three weeks minimum before judging. Same day effects from semax and selank are largely acute neurotransmitter effects. Structural BDNF driven change is slower.
• Pick a measurable endpoint first. A timed task, a reading rate, an error count on work you already do. A retrospective sense of having felt sharper is not evidence.
• Keep sleep constant. One week of poor sleep swamps every effect discussed here.
• Handle the material correctly. Reconstitution and storage errors silently give you nothing. See our reconstitution guide and storage guide.

Rule Out the Boring Causes First

This belongs before any of the above. Persistent brain fog usually has a cause that is cheaper and more effective to fix than any compound here.

Sleep is first, and it is not close. Chronic short sleep and untreated sleep apnoea produce exactly the symptom picture people reach for nootropics to solve, and our sleep peptides page is honest about the same limitation. After sleep, a thyroid panel, ferritin, vitamin B12 and vitamin D cover most of the remaining cheap explanations, and untreated anxiety and depression belong on the same list. Fatigue driven impairment has its own picture in our peptides for energy breakdown.

None of that is a disclaimer added for form. It is the part of this page most likely to actually change someone's cognition, and it costs a blood panel rather than a year of vials.

Key Takeaways

• The blood brain barrier disqualifies most peptides marketed for cognition
• Semax has the most published support, largely from one country's research programme
• Selank is an anxiolytic first, and its cognitive benefit is downstream of reduced anxiety
• Dihexa has striking rodent data, zero human trials and no long term safety profile
• Cerebrolysin got real clinical scrutiny, and that scrutiny produced ambiguous results
• Bioregulators like pinealon dodge the delivery objection but rest on thin, unreplicated evidence
• Sleep, thyroid, ferritin and B12 explain more brain fog than every compound here combined

Frequently Asked Questions

What is the best peptide for brain function?

Semax has the most published work behind it, though almost all of it comes from Russian groups and it is registered as a medicine only in Russia and Ukraine. It is the reasonable starting point for anyone determined to try this category. That says more about a thin field than about semax, because no peptide here has the large independent trial that would settle the question.

Do nootropic peptides cross the blood brain barrier?

Most do not in any meaningful quantity. Peptides are large and water loving, and the barrier is built to exclude exactly that. The ones that get anywhere are short, stable and usually intranasal, exploiting olfactory and trigeminal routes that partly bypass it. That is why semax and selank are sprays rather than injections, and it is the best single filter for judging any peptide marketed for cognition.

Is semax or selank better for focus?

Semax, if focus is the actual goal. It works through BDNF and dopaminergic signalling and is the more stimulating of the two. Selank was designed as an anxiolytic and its cognitive effect is downstream of reduced anxiety, so it helps most when worry is what degrades concentration.

Is dihexa worth trying?

Not on the current evidence. Dihexa potentiates hepatocyte growth factor signalling and the rodent synaptogenesis data are striking, but there are no published human trials, no established dose, and no long term safety data for a compound whose mechanism is driving new synapse formation. The gap between marketing and evidence is widest here.

How long before a cognitive peptide shows an effect?

Semax and selank can produce a same day subjective change, which is a large part of their appeal and the reason they are easy to over-rate. Anything working through BDNF driven structural change needs two to four weeks before a judgement is fair. Run one compound at a time against a measurable endpoint rather than a feeling.

What should I rule out before trying peptides for cognition?

Sleep first, because chronic short sleep and untreated apnoea degrade attention and memory more than any peptide here will restore. Then thyroid function, ferritin, vitamin B12 and vitamin D, all cheap to test and all capable of producing brain fog. Untreated anxiety and depression belong on the same list. A nasal spray on top of five hours of sleep a night is not a fair test of anything.